Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for Pfizer Inc.�
34.33
-0.46 (-1.32%)
Apr 1 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 34.11 - 34.84
52 week 27.51 - 35.45
Open 34.84
Vol / Avg. 32.24M/28.44M
Mkt cap 213.62B
P/E 24.22
Div/yield 0.28/3.26
EPS 1.42
Shares 6.13B
Beta 0.74
Inst. own 74%
Apr 28, 2015
Q1 2015 Pfizer Inc Earnings Call - 10:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 Pfizer Inc Earnings Release - 9:30AM EDT - Add to calendar
Apr 23, 2015
Pfizer Inc Annual Shareholders Meeting - 8:30AM EDT - Add to calendar
Mar 24, 2015
Pfizer Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 3, 2015
Pfizer Inc at Cowen Health Care Conference
Feb 10, 2015
Pfizer Inc at Biotechnology Industry Organization CEO & Investor Conference
Feb 5, 2015
Pfizer Inc Discussing Proposed Acquisition of Hospira Call (Media)
Feb 5, 2015
Pfizer Inc Discussing Proposed Acquisition of Hospira Call (Analyst and Investor)
Jan 27, 2015
Q4 2014 Pfizer Inc Earnings Call
Jan 27, 2015
Q4 2014 Pfizer Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 9.59% 18.39%
Operating margin 14.51% 25.66%
EBITD margin - 57.64%
Return on average assets 2.96% 5.34%
Return on average equity 6.72% 12.32%
Employees 78,300 -
CDP Score - 92 B

Address

235 E 42ND ST
NEW YORK, NY 10017-5703
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Pfizer Inc. is a bio pharmaceutical company. The company applies science and resources to discover, develop and manufacture healthcare products. The Company provides medicines, vaccines and consumer healthcare products. The Company operates its business through three operating segments, which include Global Innovative Pharmaceutical segment (GIP); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC), and the Global Established Pharmaceutical segment (GEP). The Company provides medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, partnerships with global public health and medical associations, regulatory inspection readiness reviews, internal audits of Pfizer-sponsored clinical trials and internal regulatory compliance processes.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 57
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 56
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 54
Bio & Compensation  - Reuters
John D Young Group President - Global Established Pharma Business
Age: 50
Bio & Compensation  - Reuters
Rady A. Johnson II Executive Vice President, Chief Compliance and Risk Officer
Age: 53
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 59
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters